Customize your JAMA Network experience by selecting one or more topics from the list below.
Fisher reviews the MATCH trial whereby clopidogrel and aspirin was compared with clopidogrel alone for secondary prevention in patients who have had a transient ischemic attack or stroke in a high-risk population with a high prevalence of other vascular risk factors. A nonsignificant trend for a reduction of the combined end point of ischemic stroke, myocardial infarction, vascular death, and rehospitalization was observed in the combination therapy group. The frequency of serious, life-threatening bleeding adverse effects was almost doubled in the combination arm. Neurologists need to be aware of these results and avoid the use of clopidogrel with aspirin in patients who have had a transient ischemic attack or stroke until evidence is provided that the combination is safe in this population.
This Month in The Archives of Neurology. Arch Neurol. 2006;63(1):13–14. doi:https://doi.org/10.1001/archneur.63.1.13
Create a personal account or sign in to: